Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05235646 · ClinicalTrials.gov registry record
Infiltration of Gadolinium Injection in Brain MR Scans Using Artificial Intelligence
A clinical trial, sponsored by Mayo Clinic.
- Completed
- Registry status
- 40
- Enrollment target
NCT05235646: Completed study, sponsored by Mayo Clinic.
NCT05235646 is a clinical trial that has completed, run by Mayo Clinic. The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05235646 has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 40 participants
- Enrollment target
Study Summary
The purpose of this research is to develop machine learning algorithms to analyze images from brain MRI to confirm that contrast agent has been correctly administered.
Primary Outcome
Correct detection of the presence of infiltration of Gadolinium contrast agent into tissue and muscleusing an artificial intelligence model. This outcome will be determined by measuring the difference in signal enhancement in the nasal mucosa or the lack of signal enhancement within the nasal mucosa.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2022-03-14 |
| Est. Completion | 2022-04-05 |
What the finished NCT05235646 record still lists
NCT05235646 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 40 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT05235646 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05235646 about?
NCT05235646 is a clinical study titled "Infiltration of Gadolinium Injection in Brain MR Scans Using Artificial Intelligence". The purpose of this research is to develop machine learning algorithms to analyze images from brain MRI to confirm that contrast agent has been correctly administered.
What is the current status of trial NCT05235646?
This trial is currently completed. The enrollment target is 40 participants. The study started on 2022-03-14. Estimated completion is 2022-04-05.
Who is sponsoring clinical trial NCT05235646?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI